Last updated: September 8, 2026
Dostarlimab-gxly, marketed by GSK as Jemperli, has shifted from a biomarker-defined salvage therapy into a broader first-line endometrial-cancer product. Its commercial trajectory depends on three factors: expansion into all-comer advanced or recurrent endometrial cancer, continued uptake of the carboplatin-paclitaxel combination, and the conversion of clinical activity in colorectal cancer and other tumors into regulatory approvals.
GSK reported Jemperli sales of approximately £310 million in 2023, up from roughly £178 million in 2022. Sales growth accelerated after the first-line endometrial-cancer indication. Jemperli remains smaller than GSK’s largest specialty products, but it is one of the company’s principal oncology growth assets (GSK, 2024a).
What is the FDA status of dostarlimab-gxly?
Jemperli is an FDA-approved PD-1-blocking monoclonal antibody for selected endometrial-cancer populations and for broader first-line use in combination with chemotherapy.
| FDA milestone |
Date |
Commercial significance |
| Initial accelerated approval for dMMR recurrent or advanced endometrial cancer after prior platinum therapy |
April 2021 |
Established Jemperli in biomarker-selected salvage treatment |
| Expanded approval with carboplatin and paclitaxel for dMMR/MSI-H primary advanced or recurrent endometrial cancer |
February 2023 |
Moved the product into first-line combination therapy |
| Conversion of the single-agent indication to traditional approval |
2023 |
Reduced reliance on confirmatory-trial status |
| Expanded first-line indication for primary advanced or recurrent endometrial cancer regardless of MMR status |
August 2024 |
Materially increased the addressable U.S. market |
The current commercial label covers:
- Jemperli monotherapy for adults with mismatch-repair-deficient, or dMMR, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen.
- Jemperli with carboplatin and paclitaxel, followed by Jemperli monotherapy, for adults with primary advanced or recurrent endometrial cancer.
The all-comer first-line expansion was based on the RUBY trial. The dMMR/MSI-H subgroup generated the strongest efficacy signal, but the overall population also supported the broader indication (FDA, 2024).
How large is the commercial market for Jemperli?
The core market is advanced or recurrent endometrial cancer, with commercial upside from earlier-line treatment and longer duration of therapy.
The United States records approximately 67,000 new endometrial-cancer cases annually, according to American Cancer Society estimates. A minority present with metastatic disease, while a larger group eventually develops recurrent disease. The eligible treatment population is therefore substantially smaller than the total incidence pool, but first-line use increases the number of patients exposed to Jemperli.
Addressable patient segments
| Segment |
Jemperli role |
Market effect |
| dMMR/MSI-H advanced or recurrent disease |
Strongest historical positioning |
High response rates and biomarker-driven prescribing |
| dMMR/MSI-H first-line disease |
Jemperli plus carboplatin and paclitaxel |
Increases treatment duration and patient reach |
| MMR-proficient or non-MSI-H disease |
First-line combination indication |
Expands the market beyond biomarker-selected patients |
| Platinum-pretreated recurrence |
Jemperli monotherapy |
Maintains a later-line treatment channel |
| Colorectal cancer |
Investigational |
Potentially large upside, but no FDA-approved colorectal indication |
| Other solid tumors |
Investigational or limited development |
Option value rather than current revenue |
Commercial penetration is likely to be highest in dMMR/MSI-H disease because the subgroup has a clear biological rationale and stronger clinical differentiation. The 2024 all-comer label materially broadens the market, but it also places Jemperli in direct competition with other checkpoint-inhibitor combinations.
What are Jemperli’s sales and financial trajectory?
Jemperli’s sales have increased rapidly from a small launch base.
| Fiscal year |
Approximate Jemperli sales |
Principal driver |
| 2021 |
Limited launch revenue |
Initial accelerated approval |
| 2022 |
About £178 million |
Increasing U.S. adoption in recurrent disease |
| 2023 |
About £310 million |
First-line dMMR/MSI-H approval and RUBY uptake |
| 2024 |
Continued growth expected |
Broader first-line use and international rollout |
GSK’s 2023 annual report identified Jemperli as a high-growth oncology product, with sales rising approximately 74% year over year to about £310 million. The company’s reporting currency is sterling, and exchange rates affect comparisons across periods (GSK, 2024a).
The financial profile has four favorable characteristics:
- A biologic product with premium oncology pricing.
- Longer treatment duration in first-line combination therapy.
- Expansion from biomarker-selected patients into an all-comer population.
- A relatively concentrated indication that can support focused commercial execution.
The principal limitation is scale. Jemperli is not yet a multibillion-pound product. Its revenue base remains dependent on endometrial cancer, and the product competes in a crowded PD-1 and PD-L1 market.
Revenue scenario framework
| Scenario |
Commercial assumptions |
Revenue implication |
| Downside |
Slow uptake outside dMMR/MSI-H disease, payer controls, competitive displacement |
Growth decelerates after initial first-line launch |
| Base case |
Sustained U.S. adoption, increasing combination use, steady European reimbursement |
Continued high-single-digit to double-digit growth from the 2023 base |
| Upside |
Broad international penetration plus a successful colorectal-cancer expansion |
Potential for Jemperli to become a major GSK oncology product |
These are strategic scenarios rather than GSK guidance. GSK has not disclosed a product-specific peak-sales target that establishes a definitive market ceiling.
Which clinical data drive Jemperli adoption?
The commercial case rests mainly on GARNET and RUBY.
GARNET trial
GARNET supported the original biomarker-defined monotherapy market. In patients with dMMR recurrent or advanced endometrial cancer, dostarlimab produced clinically meaningful response rates after prior therapy. The trial established Jemperli as a treatment option for patients with limited alternatives (FDA, 2023).
Its commercial importance is narrower than RUBY because it applies to later-line and biomarker-selected disease. It remains relevant because it supports treatment continuity after progression and gives physicians experience with the product.
RUBY trial
RUBY evaluated dostarlimab with carboplatin and paclitaxel, followed by dostarlimab maintenance, in primary advanced or recurrent endometrial cancer.
The study demonstrated progression-free-survival benefit in the overall population and a more pronounced effect in dMMR/MSI-H patients. Overall-survival data also strengthened the case for first-line use. Combination therapy changes the economics of treatment because patients receive an induction phase followed by maintenance immunotherapy rather than a short course of single-agent salvage treatment (Mirza et al., 2023; Mirza et al., 2024).
The main commercial questions are:
- How broadly oncologists use Jemperli in MMR-proficient disease.
- Whether combination toxicity affects treatment completion.
- Whether physicians favor Jemperli over competing checkpoint combinations.
- How quickly payers adopt the all-comer indication.
- Whether real-world survival data confirm the RUBY results.
How does Jemperli compare with competing drugs?
Jemperli competes primarily with pembrolizumab-based and durvalumab-based regimens in endometrial cancer. Merck’s Keytruda has broader oncology penetration, larger clinical infrastructure, and extensive use across tumor types. AstraZeneca’s Imfinzi has also gained a role in first-line endometrial cancer, particularly in biomarker-defined populations.
| Product |
Company |
Endometrial-cancer positioning |
Competitive advantage |
| Jemperli |
GSK |
Monotherapy after platinum; combination with chemotherapy in first-line disease |
Strong dMMR/MSI-H data and a broad 2024 first-line label |
| Keytruda |
Merck |
Broad checkpoint-inhibitor use, including endometrial-cancer combinations |
Large installed base and cross-tumor physician familiarity |
| Imfinzi |
AstraZeneca |
First-line combination use in selected endometrial-cancer populations |
Strong oncology presence and combination development |
| Lenvima plus Keytruda |
Eisai/Merck |
Advanced disease, especially after prior systemic therapy |
Established combination and broad clinical experience |
Jemperli’s advantage is not simply PD-1 class membership. Its competitive position depends on the RUBY data, dosing and maintenance strategy, payer access, and GSK’s ability to establish routine use outside the dMMR/MSI-H population.
What patent and exclusivity protections cover dostarlimab?
Dostarlimab is a biologic, so its exclusivity profile differs from that of a conventional small-molecule drug.
Key protection layers include:
- Composition-of-matter and antibody-related patents.
- Formulation and manufacturing patents.
- Method-of-use patents covering cancer treatment and biomarker-defined populations.
- FDA reference-product exclusivity for the biologic license application.
- Regulatory exclusivity associated with the original approval and later indication expansions.
Jemperli originated in Tesaro’s oncology portfolio. GSK acquired Tesaro in 2019 for approximately $5.1 billion, obtaining dostarlimab and other oncology assets (GSK, 2019).
The U.S. biologics framework generally provides 12 years of reference-product exclusivity from first licensure, subject to statutory rules and litigation. That period is distinct from patent expiration. Biosimilar applicants may challenge listed or asserted patents before the reference product’s exclusivity period ends, but market entry depends on the complete patent, regulatory, and litigation record.
Orange Book and Purple Book status
Jemperli is regulated as a biologic and is tracked primarily through the FDA’s Purple Book rather than the Orange Book. The relevant competitive threat is a dostarlimab biosimilar, not an ordinary ANDA generic.
The practical barriers to biosimilar entry include:
- Demonstrating analytical similarity to a complex antibody.
- Establishing comparable clinical pharmacology.
- Resolving patent disputes under the Biologics Price Competition and Innovation Act.
- Building manufacturing capacity for a sterile monoclonal antibody.
- Obtaining payer acceptance against an established branded product.
No biosimilar has yet displaced Jemperli in the U.S. market. A future biosimilar could still pressure net price, especially after regulatory exclusivity and key patent protections expire.
When could Jemperli lose exclusivity?
The exact commercial loss-of-exclusivity date depends on the relevant U.S. and international patents, regulatory exclusivity, pediatric extensions, patent-term adjustments, and litigation outcomes. Biologic exclusivity and patent expiry should not be treated as the same date.
The most important timing points are:
| Protection |
Commercial relevance |
| Reference-product biologic exclusivity |
Delays FDA approval of a biosimilar application |
| Composition and antibody patents |
Can delay or deter biosimilar launch |
| Formulation patents |
May support secondary patent positions |
| Method-of-use patents |
May protect specific indications, but do not necessarily block all biosimilar use |
| Manufacturing patents |
Can increase development and scale-up costs |
| Patent settlements |
May establish a negotiated biosimilar launch date |
A biosimilar could enter after regulatory exclusivity if it resolves patent barriers or receives a license under a settlement. A patent challenge would likely focus on validity, enforceability, and non-infringement rather than the existence of a conventional generic pathway.
Are there Paragraph IV challenges or patent lawsuits involving Jemperli?
Paragraph IV litigation is generally associated with small-molecule ANDA filings. For Jemperli, the more relevant process is the BPCIA patent dance and related biosimilar litigation.
Publicly visible Jemperli commercial risk is currently driven more by competing immuno-oncology products and clinical-label expansion than by a known near-term biosimilar launch. No major public settlement has established an imminent U.S. dostarlimab biosimilar entry date.
The absence of a public biosimilar launch date does not eliminate long-term erosion risk. It means that current pricing and volume forecasts should focus on branded competition, indication expansion, and treatment duration.
What licensing deals affect dostarlimab?
The principal transaction was GSK’s acquisition of Tesaro. The deal gave GSK control of dostarlimab and strengthened its oncology pipeline.
The acquisition had two commercial consequences:
- It placed dostarlimab inside GSK’s global oncology infrastructure.
- It linked the product to a broader portfolio that includes niraparib and other cancer assets.
GSK has not built Jemperli’s commercial position around a major external co-commercialization deal. Its growth strategy has relied primarily on internal development, combination trials, and label expansion.
What colorectal-cancer opportunity does dostarlimab have?
Dostarlimab generated substantial attention after a small investigator-led study reported complete clinical responses in patients with locally advanced dMMR rectal cancer. The result created a potential disease-erasing treatment narrative, but it is not yet a broad commercial indication.
The opportunity is attractive because colorectal cancer has a large patient population and a clinically identifiable dMMR/MSI-H subgroup. The limitation is that the initial evidence involved a small number of highly selected patients. Larger, controlled studies and longer follow-up are required before the result can support routine use or an FDA label expansion (Cercek et al., 2022).
A successful colorectal-cancer program would diversify Jemperli beyond endometrial cancer. Failure to reproduce the early response rate would leave the product commercially concentrated in gynecologic oncology.
What manufacturing and supply-chain barriers affect Jemperli?
Dostarlimab is an intravenous monoclonal antibody. Manufacturing requires mammalian-cell production, purification, viral clearance, sterile fill-finish, cold-chain distribution, and validated quality controls.
The main barriers are:
- Capacity for commercial-scale biologic production.
- Consistency across manufacturing sites.
- Control of aggregate formation and immunogenicity.
- Supply of single-use systems and sterile components.
- Cost of goods relative to long-term oncology pricing.
These barriers favor the originator during the early commercial period. They also raise the capital requirements for a future biosimilar competitor.
What generic or biosimilar entry risks exist?
Near-term generic substitution risk is low because Jemperli is a biologic. Long-term biosimilar risk is meaningful but likely to develop gradually.
The most probable erosion sequence is:
- Branded competition reduces new-patient share.
- Payers increase preferred use of lower-cost checkpoint combinations.
- A biosimilar enters selected markets after patent and regulatory barriers are resolved.
- Net price declines before prescription volume declines materially.
- GSK protects revenue through new indications, dosing strategies, and combination regimens.
A biosimilar could have greater impact in maintenance therapy than in initial combination treatment because maintenance is repeated over a longer period and is easier for payers to manage through formulary controls.
How strong is the Jemperli commercial and patent estate?
Jemperli has a strong clinical-commercial position in dMMR/MSI-H endometrial cancer and a materially broader market after the 2024 all-comer approval. Its patent estate is strategically important, but long-term value depends more on clinical differentiation and indication expansion than on patent duration alone.
Strengths include:
- Positive randomized data in first-line endometrial cancer.
- A high-value biomarker-defined population.
- A broad U.S. label after 2024.
- Maintenance-treatment economics.
- Potential colorectal-cancer expansion.
Risks include:
- Strong competition from Keytruda and Imfinzi.
- Dependence on one primary tumor type.
- Uncertain conversion of early colorectal-cancer findings into approval.
- Future biosimilar and price pressure.
- Potential payer resistance to premium combination therapy.
Key Takeaways
- Jemperli is GSK’s dostarlimab-gxly brand and a growing oncology product.
- Sales reached approximately £310 million in 2023, compared with about £178 million in 2022.
- The 2023 first-line dMMR/MSI-H indication and the 2024 all-comer expansion changed Jemperli’s market size.
- RUBY is the principal commercial trial because it supports combination therapy and maintenance treatment.
- Keytruda and Imfinzi are the main branded competitors.
- Jemperli faces biosimilar risk rather than conventional generic risk.
- Its commercial value remains concentrated in endometrial cancer.
- Colorectal cancer is the largest potential expansion opportunity, but early data require broader validation.
- GSK’s acquisition of Tesaro was the principal transaction behind Jemperli ownership.
- Long-term revenue depends on first-line penetration, international reimbursement, treatment duration, and protection from biosimilar entry.
FAQs
Is dostarlimab the same drug as Jemperli?
Yes. Dostarlimab-gxly is the nonproprietary name, and Jemperli is GSK’s U.S. brand name.
Is Jemperli approved for colorectal cancer?
No. Dostarlimab has generated strong results in small studies of dMMR rectal cancer, but colorectal cancer is not an established FDA-approved Jemperli indication.
Does Jemperli have a generic version?
No conventional generic is available. Any future competitor would generally follow the biosimilar pathway for biologic products.
Which biomarker predicts the strongest Jemperli response?
Mismatch-repair deficiency and microsatellite instability-high status are the principal biomarkers associated with the strongest clinical activity.
What is the largest financial risk to Jemperli?
The largest risk is competitive displacement in first-line endometrial cancer before GSK establishes durable use across the broader all-comer population.
References
American Cancer Society. (2024). Key statistics for endometrial cancer. https://www.cancer.org
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., Hwang, W. T., Viale, A., Tsai, S., Saltz, L. B., & Diaz, L. A., Jr. (2022). PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. New England Journal of Medicine, 386(25), 2363-2376. https://doi.org/10.1056/NEJMoa2201445
GSK. (2019). GSK completes acquisition of Tesaro, an oncology company. https://www.gsk.com
GSK. (2024a). Annual report 2023. https://www.gsk.com/investors/annual-report/
Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Lorusso, D., Drew, Y., Høgdall, C., Alarslan, D., McMeekin, D. S., & others. (2023). Dostarlimab for primary advanced or recurrent endometrial cancer. New England Journal of Medicine, 388(23), 2145-2158. https://doi.org/10.1056/NEJMoa2216334
Mirza, M. R., Chase, D. M., Slomovitz, B. M., et al. (2024). Overall survival with dostarlimab plus chemotherapy in advanced or recurrent endometrial cancer. New England Journal of Medicine.
U.S. Food and Drug Administration. (2023). Jemperli: Prescribing information and approval history. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024). FDA approves dostarlimab-gxly with chemotherapy for primary advanced or recurrent endometrial cancer. https://www.fda.gov
